[Our experience in the use of prostatilen in urology].
Prostatilen was used in 1115 patients with chronic pyelonephritis and prostatitis. It is shown that prostatilen has a corrective effect on hemocoagulation and immunity disorders, restores microcirculation, suppresses inflammation in the kidney and prostate. Thus, prostatilen is a pathogenetically sound drug for treatment in urogenital inflammation while in chronic prostatitis it can be used as a basic therapy.
Al'-Shukri
S Kh
SKh
Bobkov
Iu A
IuA
Gorbachev
A G
AG
Kuz'min
I V
IV
Tkachuk
V N
VN
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001777:Blood Coagulation / Q000187:drug effects; D002908:Chronic Disease; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D007668:Kidney / Q000098:blood supply / Q000187:drug effects; D008297:Male; D008833:Microcirculation / Q000187:drug effects; D008875:Middle Aged; D010455:Peptides / Q000627:therapeutic use*; D011467:Prostate / Q000098:blood supply / Q000187:drug effects; D011472:Prostatitis / Q000150:complications* / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology; D011704:Pyelonephritis / Q000150:complications* / Q000188:drug therapy / Q000276:immunology / Q000503:physiopathology; D014572:Urology
D000276:Adjuvants, Immunologic; D000893:Anti-Inflammatory Agents; D010455:Peptides; C069549:prostatilen